Literature DB >> 18258657

N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice.

Nicholas P Whitehead1, Catherine Pham, Othon L Gervasio, David G Allen.   

Abstract

Duchenne muscular dystrophy (DMD) is a severe degenerative muscle disease caused by a mutation in the gene encoding dystrophin, a protein linking the cytoskeleton to the extracellular matrix. In this study we investigated whether the antioxidant N-acetylcysteine (NAC) provided protection against dystrophic muscle damage in the mdx mouse, an animal model of DMD. In isolated mdx muscles, NAC prevented the increased membrane permeability and reduced the force deficit associated with stretch-induced muscle damage. Three-week-old mdx mice were treated with NAC in the drinking water for 6 weeks. Dihydroethidium staining showed that NAC treatment reduced the concentration of reactive oxygen species (ROS) in mdx muscles. This was accompanied by a significant decrease in centrally nucleated fibres in muscles from NAC-treated mdx mice. Immunoblotting showed that NAC treatment decreased the nuclear protein expression of NF-kappaB, a transcription factor involved in pro-inflammatory cytokine expression. Finally, we show that NAC treatment reduced caveolin-3 protein levels and increased the sarcolemmal expression of beta-dystroglycan and the dystrophin homologue, utrophin. Taken together, our findings suggest that ROS play an important role in the dystrophic pathogenesis, both in terms of activating damage pathways and in regulating the expression of some dystrophin-associated membrane proteins. These results offer the prospect that antioxidants such as NAC could have therapeutic potential for DMD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258657      PMCID: PMC2375717          DOI: 10.1113/jphysiol.2007.148338

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  51 in total

1.  Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice.

Authors:  Karim Hnia; Gerald Hugon; François Rivier; Ahmed Masmoudi; Jacques Mercier; Dominique Mornet
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

2.  Oxidative damage to muscle protein in Duchenne muscular dystrophy.

Authors:  J W Haycock; S MacNeil; P Jones; J B Harris; D Mantle
Journal:  Neuroreport       Date:  1996-12-20       Impact factor: 1.837

3.  Effects of stretch-activated channel blockers on [Ca2+]i and muscle damage in the mdx mouse.

Authors:  Ella W Yeung; Nicholas P Whitehead; Thomas M Suchyna; Philip A Gottlieb; Frederick Sachs; David G Allen
Journal:  J Physiol       Date:  2004-11-04       Impact factor: 5.182

4.  N-acetylcysteine increases manganese superoxide dismutase activity in septic rat diaphragms.

Authors:  E Barreiro; D Sánchez; J B Gáldiz; S N A Hussain; J Gea
Journal:  Eur Respir J       Date:  2005-12       Impact factor: 16.671

Review 5.  The role of free radicals in the pathophysiology of muscular dystrophy.

Authors:  James G Tidball; Michelle Wehling-Henricks
Journal:  J Appl Physiol (1985)       Date:  2006-11-09

6.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability.

Authors:  P W Hamer; J M McGeachie; M J Davies; M D Grounds
Journal:  J Anat       Date:  2002-01       Impact factor: 2.610

7.  The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice.

Authors:  Iwan A Williams; David G Allen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-06-15       Impact factor: 4.733

8.  Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state.

Authors:  M H Disatnik; J Dhawan; Y Yu; M F Beal; M M Whirl; A A Franco; T A Rando
Journal:  J Neurol Sci       Date:  1998-11-26       Impact factor: 3.181

9.  Oxyradical damage and mitochondrial enzyme activities in the mdx mouse.

Authors:  E Hauser; H Höger; R Bittner; K Widhalm; K Herkner; G Lubec
Journal:  Neuropediatrics       Date:  1995-10       Impact factor: 1.947

10.  Dystrophic cardiomyopathy: amplification of cellular damage by Ca2+ signalling and reactive oxygen species-generating pathways.

Authors:  Carole Jung; Adriano S Martins; Ernst Niggli; Natalia Shirokova
Journal:  Cardiovasc Res       Date:  2007-12-04       Impact factor: 10.787

View more
  101 in total

1.  Effect of N-acetylcysteine plus deferoxamine on oxidative stress and inflammation in dystrophic muscle cells.

Authors:  Luis Henrique Rapucci Moraes; Roberta Constâncio Bollineli; Daniela Sayuri Mizobuti; Leonardo Dos Reis Silveira; Maria Julia Marques; Elaine Minatel
Journal:  Redox Rep       Date:  2014-10-31       Impact factor: 4.412

2.  Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle.

Authors:  Sanjeewa A Goonasekera; Chi K Lam; Douglas P Millay; Michelle A Sargent; Roger J Hajjar; Evangelia G Kranias; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

3.  Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart.

Authors:  Claudia Colussi; Jessica Rosati; Stefania Straino; Francesco Spallotta; Roberta Berni; Donatella Stilli; Stefano Rossi; Ezio Musso; Emilio Macchi; Antonello Mai; Gianluca Sbardella; Sabrina Castellano; Cristina Chimenti; Andrea Frustaci; Angela Nebbioso; Lucia Altucci; Maurizio C Capogrossi; Carlo Gaetano
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

4.  Increased catalase expression improves muscle function in mdx mice.

Authors:  Joshua T Selsby
Journal:  Exp Physiol       Date:  2010-11-01       Impact factor: 2.969

5.  Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.

Authors:  Jessica R Terrill; Gavin J Pinniger; Jamie A Graves; Miranda D Grounds; Peter G Arthur
Journal:  J Physiol       Date:  2016-01-18       Impact factor: 5.182

6.  IFN-γ promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation.

Authors:  S Armando Villalta; Bo Deng; Chiara Rinaldi; Michelle Wehling-Henricks; James G Tidball
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

7.  Effect of short-term creatine supplementation on markers of skeletal muscle damage after strenuous contractile activity.

Authors:  Reinaldo Abunasser Bassit; Carlos Hermano da Justa Pinheiro; Kaio Fernando Vitzel; Antônio José Sproesser; Leonardo R Silveira; Rui Curi
Journal:  Eur J Appl Physiol       Date:  2009-12-03       Impact factor: 3.078

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

9.  Immunoproteasome in animal models of Duchenne muscular dystrophy.

Authors:  Chiao-Nan Joyce Chen; Ted G Graber; Wendy M Bratten; Deborah A Ferrington; LaDora V Thompson
Journal:  J Muscle Res Cell Motil       Date:  2014-06-17       Impact factor: 2.698

10.  Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle.

Authors:  Erik P Rader; Rolf Turk; Tobias Willer; Daniel Beltrán; Kei-Ichiro Inamori; Taylor A Peterson; Jeffrey Engle; Sally Prouty; Kiichiro Matsumura; Fumiaki Saito; Mary E Anderson; Kevin P Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.